https://www.tandfonline.com/doi/pdf/10.1080/14656566.2019.1695778?needAccess=true
ABSTRACT
Introduction: Schizophrenia, a devastating disorder with onset in adolescence or young adulthood,
afflicts 1% of the population leading to severe social, educational, and occupational impairments.
Lumateperone is a first-in-class investigational drug under development for the treatment of multiple
neuropsychiatric and neurodegenerative disorders including schizophrenia. Its unique receptor affinity
profile together with synergistic modulation of serotonergic, glutamatergic, and dopaminergic pathways imparts efficacy over a broad-spectrum of symptoms associated with schizophrenia.
Areas covered: This narrative drug evaluation includes a review of lumateperone tosylate (lumateperone, ITI-007, ITI-722, Intra-Cellular Therapies, Inc.) for patients with schizophrenia. This review describes
the receptor affinity profile, pharmacodynamics, pharmacokinetics, distribution, metabolism, and clinical trials that address how lumateperone could potentially emerge as an important therapeutic option
for schizophrenia patients.
Expert opinion: The unique pharmacological properties of lumateperone may provide the key to
dramatically ameliorate the symptoms of schizophrenia as indicated by some clinical trials. Future
clinical trials may be enhanced by the administration of more comprehensive long-term behavioral
measures and utilization of molecular imaging to confirm the target engagement of the many possible
sites of action. The results of ongoing and future studies will provide the evidence to determine if
lumateperone will revolutionize the therapy of schizophrenia.